Enfusion Forecast, price target & analysts
Enfusion Target price 2025 - Analyst rating & recommendation
Enfusion Classifications & Recommendation:
Enfusion Price Target
| Target Price | $11.25 |
| Price | $11.14 |
| Potential |
0.99%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Enfusion 2026 .
The average Enfusion target price is $11.25.
This is
0.99%
register free of charge
$11.25
0.99%
register free of charge
$11.25
0.99%
register free of charge
|
|
| A rating was issued by 6 analysts: 0 Analysts recommend Enfusion to buy, 5 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Enfusion stock has an average upside potential 2026 of
0.99%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 201.61 | 237.17 |
| 15.51% | 17.64% | |
| EBITDA Margin | 7.69% | 22.83% |
| 34.63% | 196.76% | |
| Net Margin | 1.41% | 5.59% |
| 62.90% | 296.86% |
8 Analysts have issued a sales forecast Enfusion 2025 . The average Enfusion sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Enfusion EBITDA forecast 2025. The average Enfusion EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Enfusion Analysts have issued a net profit forecast 2025. The average Enfusion net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.03 | 0.14 |
| 57.14% | 366.67% | |
| P/E | 79.58 | |
| EV/Sales | 4.42 |
3 Analysts have issued a Enfusion forecast for earnings per share. The average Enfusion EPS is
This results in the following potential growth metrics and future valuations:
Current Enfusion Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| William Blair |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Dec 23 2024 |
| Stifel |
Locked
➜
Locked
|
Locked | Dec 18 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
William Blair:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Dec 23 2024 |
|
Locked
Stifel:
Locked
➜
Locked
|
Dec 18 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
